To assess observational, longitudinal study assessing the effect of dimethyl fumarate on white matter integrity and cognitive functioning 6-18 months after initiation of treatment in patients with relapsing-remitting multiple sclerosis
Latest Information Update: 13 Dec 2021
At a glance
- Drugs Dimethyl fumarate (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 13 Dec 2021 New trial record
- 15 Oct 2021 Results presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis